![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Use of D/C/F/TAF With Neurologic/Psychiatric Comorbidities: AMBER Subgroup Analysis
|
|
|
CROI 2020 March 8-11
Reported by Jules Levin
Keith Dunn,1,* Richard Bruce Simonson,1 Donghan Luo,2 Jiyun Cai,3 David Anderson1
1Janssen Scientific Affairs, LLC, Titusville, NJ; 2Janssen Research & Development, LLC, Titusville, NJ; 3Janssen Research & Development, LLC, Spring House, PA.
![0316201](../images/031620/031620-12/0316201.gif)
![0316202](../images/031620/031620-12/0316202.gif)
![0316203](../images/031620/031620-12/0316203.gif)
![0316204](../images/031620/031620-12/0316204.gif)
![0316205](../images/031620/031620-12/0316205.gif)
![0316206](../images/031620/031620-12/0316206.gif)
![0316207](../images/031620/031620-12/0316207.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|